You are here

obesity

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

BioSpace

Flag link:

Obalon Scores Funding on the Heels of Obesity Market Shift

Obalon Scores Funding on the Heels of Obesity Market Shift

Medical Devices and Diagnostics Industry

Flag link:

LNC Therapeutics Acquires Exclusive License for Microbes Potentially Related to Obesity

LNC Therapeutics Acquires Exclusive License for Microbes Potentially Related to Obesity

CP Wire

LNC Therapeutics

Flag link:

Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs

Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs

Forbes

Flag link:

Novo Nordisk adds to diabetes pipeline with Evotec deal

Novo Nordisk adds to diabetes pipeline with Evotec deal

Fierce Biotech

drug development

small molecule drugs

Flag link:

Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?

Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?

Fierce Pharma

Flag link:

Omada Health launches new programs for obesity-related diseases

Omada Health launches new programs for obesity-related diseases

Healthcare Dive

digital therapeutics

Flag link:

Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

Yahoo/Zacks.com

Flag link:

Building up its rare obesity pipeline, Rhythm Pharma to raise $150M

Building up its rare obesity pipeline, Rhythm Pharma to raise $150M

Endpoints

Rhythm Pharmaceuticals

Flag link:

Gut Microbes Associated With Obesity May Contribute to Depression and Anxiety

Gut Microbes Associated With Obesity May Contribute to Depression and Anxiety

CP Wire

Flag link:

Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study

Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study

Fierce Pharma

Flag link:

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

Endpoints

Flag link:

Gelesis touts study of hydrogel obesity drug

Gelesis touts study of hydrogel obesity drug

Drug Delivery Business News

Flag link:

Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall

Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall

Endpoints

Rhythm Pharmaceuticals

Flag link:

Novo focuses on new obesity therapy Semaglutide

Novo focuses on new obesity therapy Semaglutide

GoInPharma

Flag link:

Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?

Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?

Endpoints

Flag link:

Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

Reuters

Flag link:

J&J unveils new obesity, arthritis collaborations, shares its molecule library

J&J unveils new obesity, arthritis collaborations, shares its molecule library

Fierce Biotech

rheumatoid arthritis

molecule library

drug development

Flag link:

Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1

Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1

Fierce Pharma

Flag link:

Zafgen starts comeback with first data on replacement weight loss drug

Zafgen starts comeback with first data on replacement weight loss drug

Fierce Biotech

Flag link:

Pages